Allspring Global Investments Holdings LLC Sells 10,390 Shares of Sanofi $SNY

Allspring Global Investments Holdings LLC lowered its stake in Sanofi (NASDAQ:SNY) by 7.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 121,032 shares of the company’s stock after selling 10,390 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Sanofi were worth $6,023,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of SNY. Raymond James Financial Inc. grew its stake in Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares in the last quarter. Regal Partners Ltd boosted its holdings in shares of Sanofi by 102.3% in the 2nd quarter. Regal Partners Ltd now owns 1,548,204 shares of the company’s stock valued at $74,794,000 after buying an additional 782,838 shares during the last quarter. NewEdge Advisors LLC grew its stake in shares of Sanofi by 1,853.1% in the second quarter. NewEdge Advisors LLC now owns 731,208 shares of the company’s stock valued at $35,325,000 after buying an additional 693,770 shares in the last quarter. American Century Companies Inc. increased its holdings in Sanofi by 29.3% during the second quarter. American Century Companies Inc. now owns 1,959,185 shares of the company’s stock worth $94,648,000 after buying an additional 443,941 shares during the last quarter. Finally, Franklin Resources Inc. increased its holdings in Sanofi by 9.9% during the second quarter. Franklin Resources Inc. now owns 4,274,410 shares of the company’s stock worth $206,497,000 after buying an additional 384,902 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Sanofi Stock Up 1.4%

Shares of SNY opened at $48.17 on Wednesday. The firm has a market cap of $117.49 billion, a P/E ratio of 11.28, a price-to-earnings-growth ratio of 1.18 and a beta of 0.45. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.30 and a current ratio of 1.06. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The firm’s 50-day simple moving average is $49.34 and its 200 day simple moving average is $48.87.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 24th. The company reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $1.31. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company had revenue of $15.46 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter in the previous year, the company posted $2.25 earnings per share. The business’s revenue was down 7.5% on a year-over-year basis. On average, analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SNY. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Cowen reiterated a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. Barclays restated an “equal weight” rating on shares of Sanofi in a research note on Tuesday. Finally, HSBC reaffirmed a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.